American National Bank & Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

American National Bank & Trust’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5K	Sell	20 -55	-73%	-$37.4K	﹤0.01%	466
2026 Q1	$57.9K	Sell	75 -1	-1%	-$766	0.01%	345
2025 Q4	$58.7K	Hold	76	–	–	0.01%	351
2025 Q3	$42.7K	Buy	76 +6	+9%	+$3.39K	﹤0.01%	378
2025 Q2	$36.8K	Hold	70	–	–	﹤0.01%	411
2025 Q1	$44.4K	Buy	+70	New	+$48.1K	﹤0.01%	346
2023 Q3	–	Sell	-10	Closed	-$7.18K	–	635
2023 Q2	$7.18K	Hold	10	–	–	﹤0.01%	436
2023 Q1	$8.22K	Hold	10	–	–	﹤0.01%	412
2022 Q4	$7K	Sell	10 -3	-23%	-$2.21K	﹤0.01%	408
2022 Q3	$9K	Sell	13 -28	-68%	-$17.6K	﹤0.01%	376
2022 Q2	$24K	Buy	41 +31	+310%	+$20.1K	0.01%	235
2022 Q1	$7K	Buy	+10	New	+$6.33K	﹤0.01%	338
2021 Q2	–	Sell	-10	Closed	-$5K	–	312
2021 Q1	$5K	Buy	+10	New	+$4.87K	﹤0.01%	232
2017 Q1	–	Sell	-4	Closed	-$1K	–	314
2016 Q4	$1K	Buy	+4	New	+$1.52K	﹤0.01%	273

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

American National Bank & Trust's REGN Position: Q2 2026 in Review

American National Bank & Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 73% in Q2 2026, selling an estimated $37.4K and leaving 20 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #466.

American National Bank & Trust first reported a position in REGN in Q4 2016 and has held it in 14 quarters since. The position peaked at $58.7K in Q4 2025. 387 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

American National Bank & Trust held 20 shares of Regeneron Pharmaceuticals worth $12.5K as of Q2 2026.
American National Bank & Trust sold 55 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $37.4K.
Regeneron Pharmaceuticals made up ﹤0.01% of American National Bank & Trust's portfolio in Q2 2026, its #466 holding.
American National Bank & Trust first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 14 quarters since.
American National Bank & Trust's Regeneron Pharmaceuticals position peaked at $58.7K in Q4 2025.
387 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on American National Bank & Trust's 13F filing for Q2 2026, filed 22 Jul 2026.